Search dm+d | Analyse prescribing for this drug | See prices paid for this drug and its variants
| Name | Eltrombopag 50mg tablets |
| BNF code | 0901040C0AAABAB |
| Virtual Therapeutic Moiety | Eltrombopag |
| Date identifier became valid | 9 May 2023 |
| Previous product identifier | 441486009 |
| Basis of preferred name | rINN - Recommended International Non-proprietary |
| Prescribing status | Valid as a prescribable product |
| Sugar free | ✗ |
| Gluten free | ✗ |
| Preservative free | ✗ |
| CFC free | ✗ |
| Dose form | Discrete |
| Unit dose form size | 1.000 |
| Unit dose form units | tablet |
| Unit dose unit of measure | tablet |
| Virtual Product Ingredient | |
|---|---|
| Ingredient | Eltrombopag olamine |
| Basis of pharmaceutical strength | Based on Base Substance |
| Basis of strength substance identifier | 432005001 |
| Strength value numerator | 50.000 |
| Strength value numerator unit | mg |
| Ontology Drug Form & Route | |
| Form & Route | tablet.oral |
| Dose Form | |
| Formulation | Oral tablet |
| Drug Route | |
| Route | Oral |
| Controlled Drug Prescribing Information | |
| Controlled Drug category | No Controlled Drug Status |
| Actual Medicinal Products | |
| Revolade 50mg tablets (Novartis Pharmaceuticals UK Ltd) | |
| Virtual Medicinal Product Packs | |
| Eltrombopag 50mg tablets 28 tablet | |
dm+d data retrieved from TRUD: release NHSBSA_11.2.0_20241118000001, imported on 19th November 2024 at 03:53:26.